{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "11249496", "DateCompleted": {"Year": "2001", "Month": "04", "Day": "05"}, "DateRevised": {"Year": "2019", "Month": "09", "Day": "15"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "1465-6566", "JournalIssue": {"Volume": "1", "Issue": "5", "PubDate": {"Year": "2000", "Month": "Jul"}}, "Title": "Expert opinion on pharmacotherapy", "ISOAbbreviation": "Expert Opin Pharmacother"}, "ArticleTitle": "Summary from the 153rd meeting of the American Psychiatric Association. 13-18 May 2000, Chicago, Illinois, USA.", "Pagination": {"StartPage": "1067", "EndPage": "1069", "MedlinePgn": "1067-9"}, "Abstract": {"AbstractText": ["The annual meeting of the American Psychiatric Association focuses on a variety of topics, including those on psychopharmacology. The latest developments are typically those found in the New Research sections, which is where this summary will focus."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "University of Miami, Department of Psychiatry & Behavioural Sciences, Miami, FL, USA. pgoodnick@aol.com"}], "Identifier": [], "LastName": "Goodnick", "ForeName": "P J", "Initials": "PJ"}], "PublicationTypeList": ["Congress"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Expert Opin Pharmacother", "NlmUniqueID": "100897346", "ISSNLinking": "1465-6566"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antidepressive Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Antipsychotic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Psychotropic Drugs"}, {"RegistryNumber": "0DHU5B8D6V", "NameOfSubstance": "Citalopram"}, {"RegistryNumber": "12794-10-4", "NameOfSubstance": "Benzodiazepines"}, {"RegistryNumber": "3G0285N20N", "NameOfSubstance": "Pirenzepine"}, {"RegistryNumber": "3XMK78S47O", "NameOfSubstance": "Testosterone"}, {"RegistryNumber": "N7U69T4SZR", "NameOfSubstance": "Olanzapine"}], "MeshHeadingList": [{"QualifierName": ["therapeutic use"], "DescriptorName": "Antidepressive Agents"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antipsychotic Agents"}, {"QualifierName": [], "DescriptorName": "Benzodiazepines"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Bipolar Disorder"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Citalopram"}, {"QualifierName": ["drug therapy", "psychology"], "DescriptorName": "Depressive Disorder"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Hypericum"}, {"QualifierName": [], "DescriptorName": "Olanzapine"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": ["analogs & derivatives", "therapeutic use"], "DescriptorName": "Pirenzepine"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Psychiatry"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Psychotropic Drugs"}, {"QualifierName": [], "DescriptorName": "Societies, Scientific"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Testosterone"}, {"QualifierName": [], "DescriptorName": "United States"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2001", "Month": "3", "Day": "16", "Hour": "10", "Minute": "0"}, {"Year": "2001", "Month": "4", "Day": "6", "Hour": "10", "Minute": "1"}, {"Year": "2001", "Month": "3", "Day": "16", "Hour": "10", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["11249496", "10.1517/14656566.1.5.1067"]}}], "PubmedBookArticle": []}